Deva Holding A.s. · BIST:DEVA

Deva Holding A.s — Investor Presentation

15 slides from Deva Holding A.s's investor presentation

  1. Slide 1: Your reliable source for high quality pharmaceuticals

    a LT a “* your reliable sourcem , fer hiah gustity Pharnaceut casi

  2. Slide 2: Content

    Content  Milestones  Manufacturing Capabilities  Development Capabilities  Sales & Marketing Power  International Markets 22

  3. Slide 3: Milestones

    Milestones 2 1958: Establishment of Deva Pharmaceuticals 1986: DEVA listed at the Istanbul Stock Exchange 2006: Acquisition of DEVA by EastPharma 2007-2009: Restructuring & Construction of 4 new factories 2008: Agreement with Roche 2009: Creation of Deva R&D center 2010: APA Agreement with BM

  4. Slide 4: Milestones

    Milestones 2011: API Facility of Zentiva/Sanofi Aventis has been acquired 2011: Construction of Solid Oncology Manufacturing Site 2011: Receiving First EU-GMP certificates by Germany 2011: Exports started to more than 20 Countries 2012: BFS Technology and expantion of Sterile Manufacturing 201

  5. Slide 5: Manufacturing Capabilities

    Manufacturing Capabilities Çerkezköy Headquarter Kartepe (Tekirdağ) (İstanbul) (İzmit) 5

  6. Slide 6: Manufacturing Capabilities: Çerkezköy Facilities

    Manufacturing Capabilities Çerkezköy Manufacturing Facilities  Semi Solid Production -Syrup, drops, sprays, creams, gels, suppository, drop filling  Inhaler Production -MDI, DPI,Nebules 66

  7. Slide 7: Manufacturing Capabilities: Çerkezköy Facilities

    Manufacturing Capabilities Çerkezköy Manufacturing Facilities  Beta-lactam Production in two separately dedicated buildings of Cephalosporin and Penicilin. -Tablet/film tablet, Powder, Sterile powder injectable  Sterile&Non-Sterile Hormone Production  Sterile and solid Oncology Production  API P

  8. Slide 8: Manufacturing Capabilities: Kartepe Facilities

    Manufacturing Capabilities Kartepe Manufacturing Facilities  Sterile Production -Vials, ampoules, lyophilized  BFS (Blow-Fill-Seal) Production -SVP( Ophthalmic products, eye drops) -LVP (polyethylene infusion vials) 88

  9. Slide 9: Manufacturing Capabilities: Total Production Capacity

    Manufacturing Capabilities ABILITY TO PRODUCE DIFFERENT PHARMACEUTICAL FORMS TOTAL PRODUCTION CAPACITY: 1 Billion packs*  7billion Tablets  1,6billion Capsules  800mio Injectables (ampoules & vials)  20mio BFS LVP  64mio BFS SVP  20mio Sterile Pomads  51mio packs of Gels & Ointments  61mio p

  10. Slide 10: Our Sales & Marketing Capabilities

    Our Sales & Marketing Capabilities Deva is one of the leading generic players in Turkey UNIT MARKET SHARE IN TURKEY % IBRAHIM 7,5% BILIM 6,6% BAYER 6,1% DEVA 5,2% SANOFI 5,2% ULAGAY 4,0% GLAXOSMITHKLINE 3,7% NOVARTIS 3,5% SANTA FARMA 3,2% PFIZER 2,9% Deva ranks 2nd among Generic companies and 4th am

  11. Slide 11: Product Development Capabilities R&D Center

    Product Development Capabilities R&D Center  150 Scientists  Finished dosage form & API research and development  Above 300 molecules in Turkish Market  Developments for US and EU Markets 11 11

  12. Slide 12: International Markets

    International Markets  Dedicated Regulatory Team of 22 people  182 MA’s in 20 emerging markets  163 Submissions under review in 26 emerging markets  11 MA approvals in EU, CH&NZ and 17 Submissions waiting for Approvals in EU/US/NZ/AU/SA/CH 12

  13. Slide 13: International Markets Business Models

    International Markets Busines Models:  Distribution  Out-license & Supply  Contract manufacturing  API export  Deva branded sales in Europe 13 13

  14. Slide 14: DEVA World

    DEVA World | | Agrgement Closed || Under Negotiation i Pent Paes

  15. Slide 15: Thank You For Your Interest

    _ Thank You For Your Interest

Deva Holding A.S. — Investor Presentation on 6ix